Richard J. Daly currently serves as the CEO of Catalyst Pharmaceuticals, Inc., a role he will officially start on January 1, 2024. He's had a busy career, previously holding executive positions like President at CARsgen Therapeutics and COO at Beyond...

Richard J. Daly currently serves as the CEO of Catalyst Pharmaceuticals, Inc., a role he will officially start on January 1, 2024. He's had a busy career, previously holding executive positions like President at CARsgen Therapeutics and COO at Beyond Springs Inc. Before that, he was the CEO of Neuralstem, Inc. and part of Broadridge Financial Solutions as CEO and President after it spun off from ADP. His leadership style is heavily focused on performance metrics and aligning executive pay with company success. In 2019, he earned over $10 million, showing the connection between his performance and compensation, which is structure to reward achievement. He has a strong background in finance and management, known for running the U.S. diabetes subsidiary of AstraZeneca where he managed $1.2 billion in revenue. Daly is also no stranger to the stock market; his holdings fluctuated significantly, peaking around $36 million in 2023. His insights into the pharmaceutical and fintech sectors make him a key player in these industries.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Catalyst Pharmaceutical CEOs

C

Richard J. Daly

CEO of Catalyst Pharmaceutical

Education

Not specified

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1964 - 61 years ago

CEO of Catalyst Pharmaceutical for

1 year 5 months (Jan 2024 - Present)

Previous Experience

President of CARsgen Therapeutics Corporation, Chief Operating Officer at Beyond Springs Inc., CEO of Neuralstem, Inc.

Rivals

Competitors/colleagues of Richard J. Daly

Holdings

See how much did Richard J. Daly make over time.

Richard J. Daly has been actively involved in stock trading, particularly with his previous company Broadridge Financial Solutions. His stock portfolio showed some significant ups and downs; for example, he held shares worth $36 million in 2023 and saw that...

Richard J. Daly has been actively involved in stock trading, particularly with his previous company Broadridge Financial Solutions. His stock portfolio showed some significant ups and downs; for example, he held shares worth $36 million in 2023 and saw that number dip to about $28 million in early 2024. This fluctuation indicates a strong commitment to his investments, especially after his long career in executive roles. His financial expertise spans several high-profile positions in big companies, making his investment choices noteworthy, reflecting his confidence in the firms he leads and serves. It's interesting to note how much he has had riding on these stock holdings over the years, which emphasizes his deep involvement in the financial world.

Loading...

Total Stock Sold

$333.63M

BR

$333.35M

3,964,419 BR shares

CPRX

$277.86K

17,323 CPRX shares

What if they kept their stock?

If Richard J. Daly didn't sell their stock, today they would have:
Extra BR3,964,419 shares worth $494.13M and CPRX17,323 shares worth $78.13K.
This is 48.13% and $160.57M more than what they got when they sold the stock.

Charitable Transactions

BR

161,855.028 shares

BR

Recent Charitable Transactions

BR

2,000 shares

BR

Nov 21, 2024

Charity

BR

2,700 shares

BR

Feb 12, 2021

Charity

BR

2,186.028 shares

BR

Nov 26, 2019

Charity

BR

28,079 shares

BR

Sep 11, 2018

Charity

BR

40,890 shares

BR

Aug 19, 2016

Charity

BR

86,000 shares

BR

Dec 19, 2012

Charity

Insider Trading

See recent insider trades of Richard J. Daly.

BR

2,000 shares

BR

Nov 21, 2024

Charity

BR

$4.56M

BR at $207.66/share

Sep 6, 2024

Sale

BR

1,239 shares

BR

Aug 13, 2024

Received

CPRX

$276.73K

CPRX at $15.98/share

Jun 4, 2024

Sale

BR

$1.54M

BR at $185.40/share

Aug 28, 2023

Sale

BR

$12.85M

BR at $178.29/share

Aug 21, 2023

Sale

BR

$9.14M

BR at $179.02/share

Aug 18, 2023

Sale

BR

898 shares

BR

Aug 15, 2023

Received

BR

$13.16M

BR at $175.59/share

Aug 26, 2022

Sale

BR

1,523 shares

BR

Aug 10, 2022

Received

Compensation History

See how much did Richard J. Daly make over time.

Daly's compensation package has been substantial and performance-based, with 2019 being a standout year when he received over $10 million. His package typically includes a base salary, bonuses, and stock options to align his interests with company success. For instance, he earned a bonus of $1.2 million in 2019 based on hitting performance goals. The structure allows for annual reviews and possible increases to his base salary, making sure that high performance is rewarded. This approach ensures that he stays focused on achieving results that benefit the entire company, aligning his success with the growth of Catalyst Pharmaceuticals. Interestingly, his payments also reflect how well the companies he worked for performed in the market, a strategy aimed at motivating leaders to push for better results.

Year

2019

Total Compensation

$3.51M

Salary

$855.58K

Board Justification

The compensation philosophy aims to align executive compensation with company performance, ensuring a significant portion of pay is performance-based and tied to the company's financial success and shareholder value.

Bonus

$1.27M

Board Justification

Annual cash incentive compensation based on performance metrics including financial goals, client satisfaction, and strategic leadership goals, resulting in a payout of 109% of target.

Other

$55.76K

Board Justification

Other compensation includes contributions to retirement plans, insurance premiums, and charitable contributions matching.

Restricted Stock

$1.32M(11.05K RSU)

Board Justification

Performance-based RSUs granted on October 1, 2019, vesting based on achievement of performance goals over fiscal years 2020 and 2021, with 120% of target shares earned.

Performance Metrics

Performance metrics include financial goals, client satisfaction, and strategic leadership goals.

Other Catalyst Pharmaceutical CEOs

Here are other CEOs of Catalyst Pharmaceutical

Patrick J. McEnany

Ex-CEO of Catalyst Pharmaceutical

May 2014 - December 2023